Do premarketing trials help to predict drug-related iatrogenic effects in elderly patients?;Apport des essais pré-AMM à la connaissance du risque iatrogène chez la personne âgée

Therapie

Volumn 59, Issue 2, 2004, Pages 233-236

  Bouvenot, Gilles ^a   Villani, Patrick ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Clinical trials; Drug approval; Drug related iatrogenic effects; Elderly

Indexed keywords

ANTIHYPERTENSIVE AGENT; NEW DRUG;

CANCER; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; ELDERLY CARE; ETHICS; GERIATRIC DISORDER; HUMAN; HYPERTENSION; IATROGENIC DISEASE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 3543101365     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004045     Document Type: Conference Paper

References (17)

1. Dent TH, Hawke S. Too soon to market. BMJ 1997; 315: 1248-9
2. Avorn J. Including elderly people in clinical trials. BMJ 1997; 315: 1033-4
3. Lassale C, Piette F, Jolliet P. Drug effects in elderly subjects: from the pharmacologic target to the risk-benefit. Round Table 5 of the 16th National Clinical Pharmacology Workshop. Thérapie 2001; 56: 363-7
4. Food and Drug Administration. Guideline for the study of drugs likely to be used in the elderly. J Geriatr Drug Ther 1990; 5: 5-7
5. European Agency for the Evaluation of Medicinal Products (EMEA). 1995 Note for guidance on studies in support of special populations: geriatric. CPMP/ICH/379/95. London [online]. Available from URL: http://www.emea.eu.int/ pdfs/human/ich/037995en.pdf [Accessed 2004 May 19]
6. Bellissant E, Courcier-Duplantier S, Blin O, et al. Place de la relation pharmacocinétique-pharmacodynamique dans le développement des médicaments. Thérapie 2002; 57: 347-57
7. Berdeu D, Herve C, Fourcade J. Clinical trials in the elderly: ethical and methodologic considerations. Rev Med Interne 2000; 21: 614-22
8. Adams J, Silverman M, Musa D, et al. Recruiting older adults for clinical trials. Control Clin Trials 1997; 18: 14-26
9. Bouvenot G. Comment prévenir le risque thérapeutique médicamenteux? Rev Med Interne 2001; 22: 1237-43
10. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-7
11. Staessen JA, Fagard R, Thijs L, et al. Subgroup and per-protocol analysis of the randomized european trial on isolated systolic hypertension in the elderly. Arch Intern Med 1998; 158: 1681-91
12. Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999; 353: 793-6
13. Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. BMJ 1997; 315: 1059
14. Bayer A, Tadd W. Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study. BMJ 2000; 321 (7267): 992-3
15. Black DM, Cummings SR, Karpf DB. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2000; 360: 7-22
17. Cameron HJ, William BO. Clinical trials in the elderly: should we do more? Drugs Aging 1996; 9: 307-10